Global Diagnostic Radiopharmaceuticals And Contrast Media Market Size By Type (Radiopharmaceuticals, Contrast Media), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Diagnostic Radiopharmaceuticals and Contrast Media Market was valued at USD 9.4 billion in 2023 and is projected to surpass USD 17.6 billion by 2031, expanding at a CAGR of 8.3% during the forecast period (2023–2031). This growth is attributed to the rising incidence of chronic diseases, technological advancements in diagnostic imaging, and increasing awareness and early detection practices globally. Radiopharmaceuticals and contrast media play a critical role in enhancing the quality and accuracy of diagnostic procedures such as PET, SPECT, CT, and MRI scans. The integration of nuclear medicine with personalized healthcare and the growing demand for non-invasive diagnostic methods are further accelerating market growth.

Drivers:

Rising Prevalence of Chronic Diseases

The global burden of diseases such as cancer, cardiovascular disorders, and neurological conditions continues to rise, necessitating advanced imaging techniques. Radiopharmaceuticals and contrast media aid in early and accurate diagnosis, significantly improving treatment outcomes.

Technological Advancements in Diagnostic Imaging

The evolution of hybrid imaging modalities like PET/CT and SPECT/CT has increased the demand for specialized radiopharmaceuticals and contrast agents. Innovations in molecular imaging and the development of targeted imaging agents are driving this trend.

Increased Focus on Early Disease Detection

Healthcare providers are prioritizing early and accurate diagnosis to enhance treatment efficacy. Contrast media and radiopharmaceuticals provide high-contrast resolution and detailed imaging, supporting this clinical objective.

Restraints:

Stringent Regulatory Environment

The market is heavily regulated due to the radioactive nature of these substances and their impact on human health. Lengthy approval timelines and compliance requirements may hamper the timely launch of new products.

High Cost of Diagnostic Procedures

Advanced imaging techniques, especially those utilizing radiopharmaceuticals, involve substantial costs for both the product and the imaging equipment, limiting their accessibility in cost-sensitive markets.

Opportunity:

Rising Demand in Emerging Markets

Expanding healthcare infrastructure and increased investment in diagnostic services in emerging economies, particularly in Asia-Pacific and Latin America, are creating new avenues for market growth.

Development of Novel Radiotracers and Contrast Agents

Research in targeted radiotracers and safer, more effective contrast agents is opening up opportunities for players to address unmet clinical needs, particularly in oncology and cardiology.

Market by System Type Insights:

SPECT Radiopharmaceuticals accounted for the largest market share in 2023 due to their widespread use in cardiovascular and neurological imaging. PET radiopharmaceuticals are expected to grow at the fastest pace during the forecast period, supported by their superior imaging quality and increasing use in oncology diagnostics.

In the contrast media category, iodinated contrast agents dominated the market due to their extensive application in CT imaging. However, gadolinium-based agents used in MRI are anticipated to see significant growth owing to rising MRI adoption globally.

Market by End-use Insights:

Hospitals represented the largest end-use segment in 2023, owing to the high volume of diagnostic imaging procedures and advanced infrastructure. Diagnostic imaging centers are expected to witness the highest growth, driven by outpatient services, cost efficiency, and faster imaging turnaround.

Market by Regional Insights:

North America held the largest market share in 2023, driven by advanced healthcare systems, high per capita healthcare expenditure, and strong presence of leading manufacturers. Asia-Pacific is projected to grow at the fastest rate, spurred by rapid improvements in healthcare infrastructure, rising healthcare awareness, and increasing adoption of advanced diagnostic imaging technologies in countries like China and India.

Competitive Scenario:

Key players in the Global Diagnostic Radiopharmaceuticals and Contrast Media Market include GE HealthCare, Bayer AG, Bracco Imaging S.p.A., Lantheus Holdings, Curium, Jubilant Radiopharma, Cardinal Health, Guerbet, and Nordion (Canada) Inc. These companies are actively investing in R&D, launching new products, and forming strategic alliances to strengthen their market positions.

Recent Developments:

In 2023, Bayer AG launched a new gadolinium-based contrast agent optimized for low-dose MRI procedures.

GE HealthCare expanded its PET radiopharmaceutical production facilities in North America in 2024 to meet increasing demand.

In 2025, Curium announced a collaboration with a biotech startup to develop next-generation oncology-targeted radiotracers.

Scope of Work – Global Diagnostic Radiopharmaceuticals and Contrast Media Market

Report Metric Details

Market Size (2023) USD 9.4 billion

Projected Market Size (2031) USD 17.6 billion

CAGR (2023–2031) 8.3%

Market Segments By System Type (SPECT, PET, Iodinated, Gadolinium), By End-use (Hospitals, Diagnostic Imaging Centers), By Region

Growth Driv